Lead Product(s) : Pozelimab
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pozelimab Safety In Pediatric CHAPLE Disease (1–5 Years)
Details : Pozelimab is a Antibody drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Chaple Disease.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
August 26, 2025
Lead Product(s) : Pozelimab
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Deucravacitinib
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis
Details : Deucravacitinib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Takayasu Arteritis.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 10, 2025
Lead Product(s) : Deucravacitinib
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NT-501
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 14, 2025
Lead Product(s) : NT-501
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Inebilizumab
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase IV
Sponsor : Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
January 18, 2024
Lead Product(s) : Inebilizumab
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase IV
Sponsor : Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Inebilizumab
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
December 22, 2023
Lead Product(s) : Inebilizumab
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Satralizumab
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase IV
Sponsor : Chugai Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
March 08, 2022
Lead Product(s) : Satralizumab
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase IV
Sponsor : Chugai Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase IV
Sponsor : Jazz Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 16, 2021
Lead Product(s) : Cannabidiol
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase IV
Sponsor : Jazz Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegcetacoplan
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase IV
Sponsor : SFJ Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In the study, EMPAVELI met the primary endpoint, demonstrating superiority to Soliris for the change from baseline in hemoglobin level at Week 16 with an adjusted mean increase of 3.84 g/dL of hemoglobin.
Product Name : Empaveli
Product Type : Peptide
Upfront Cash : Inapplicable
May 14, 2021
Lead Product(s) : Pegcetacoplan
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase IV
Sponsor : SFJ Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KRN23
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
April 12, 2021
Lead Product(s) : KRN23
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KRN23
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
April 12, 2021
Lead Product(s) : KRN23
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable